DOCSLIB.ORG

New Year… Brain Function Nor on Animal Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Year… Brain Function Nor on Animal Studies EDITORIAL 1 Neurologists, Psychiatrists, and Neuro- ....................................................................................... surgeons. Papers should be of direct clinical relevance and so we will not J Neurol Neurosurg Psychiatry: first published as on 16 December 2004. Downloaded from generally publish papers on normal New year… brain function nor on animal studies. We hope that these changes will provide M N Rossor, M G Hanna a quick decision for our authors whilst reducing the burden on reviewers. ................................................................................... Nevertheless prioritising between good papers remains very difficult and to assist this we have established a weekly editorial meeting. ast year we said goodbye to Ian burden we have tried to make an early As we enter 2005 we reiterate our Whittle whom we thank for all his decision on priority for the journal with thanks to reviewers and authors and Lhard work and welcome Peter the result that over a third of papers do hope to continue to attract similar high Warnke from Liverpool as our new not go out to review. This will include quality manuscripts to those we have Associate Editor for Neurosurgery. We many papers that are well conducted handled over the last year. also say goodbye to many members of and worthy of publication but which we J Neurol Neurosurg Psychiatry 2005;76:1 the editorial board and welcome new consider are not best suited to the JNNP, faces. The vitality of the journal rests usually because they are too specialised. ...................... with its reviewers and authors. We In order to assist authors with the Authors’ affiliations listed our reviewers in the December decision of whether to submit to the Martin N Rossor, Michael G Hanna, Institute issue and reiterate our thanks to them. journal we have revised the web- of Neurology, Queen Square, London WC1N With over two thousand submissions a site guidelines. In summary we wish 3BG, UK year the burden on unpaid reviewers to attract papers of general interest Correspondence to: Professor Martin Rossor; forever increases. In order to reduce the to the multi-disciplinary readership of [email protected] EDITORIAL ....................................................................................... Migraine Anxiety disorders Migraine2anxiety related dizziness (MARD): a new disorder? J M Furman, C D Balaban, R G Jacob, D A Marcus http://jnnp.bmj.com/ ................................................................................... Balance disorders izziness is a common complaint Thus, it is not surprising that some that can result from abnormalities patients with dizziness may suffer from Figure 1 Venn diagram of the interfaces of the vestibular apparatus of the a combination of a balance disorder, among migraine, anxiety, and balance on October 1, 2021 by guest. Protected copyright. D disorders. The central sector, which denotes the inner ear and of those portions of the migraine, and an anxiety disorder, a three way interface, represents an hypothesised central nervous system (CNS) that symptom complex that we propose to new ailment, migraine2anxiety related process information from the peripheral name migraine2anxiety related dizzi- dizziness (MARD). vestibular system and other senses, ness (MARD) (fig 1). The general particularly vision and somatosensation. recognition of MARD may be limited Recently, two CNS disorders, migraine because of the fragmented nature of our DEFINITIONS: DISORDER, and anxiety, have been recognised as healthcare system, where specialists in SYNDROME, DEFINING being commonly associated with dizzi- one field, such as psychiatry or neurol- SYMPTOMS, AND ASSOCIATED ness.12 These associations may be an ogy, fail to recognise phenomena known SYMPTOMS expression of an aetiological relation- to specialists in other fields, such as Medical conditions are diagnosed by a ship, for example, dizziness caused by otoneurology. variety of signs and symptoms. Specific migraine, or dizziness caused by anxi- This editorial will focus on the patho- constellations of signs and symptoms ety; alternatively, migraine or anxiety physiology and clinical issues relating to are usually called syndromes, whereas a may influence the presentation of a MARD, including the interfaces among disorder is ideally identified by specific balance disorder. For example, chronic balance disorders, migraine, and anxi- pathophysiological mechanisms. Some dizziness may become more disabling ety. We use current epidemiological data diagnostic systems distinguish between during the added stress of a migraine and studies of pathogenesis to develop symptoms necessary for the diagnosis of headache or panic attack. In addition, comorbidity models. These models serve the disorder (defining symptoms),6 and dizziness occurs comorbidly with both as hypotheses that may lead to possible those that are associated but not defin- migraine headache and anxiety disor- treatment options for many patients ing (associated symptoms). Although ders.34Finally, there is increased comor- with dizziness, including those with associated symptoms occur with bidity between anxiety and migraine.5 MARD. increased prevalence in a disorder, they www.jnnp.com 2 EDITORIAL but not in patients with tension-type Spreading headache.13 Conversely, migraine was depression reported by 38% of 200 consecutive J Neurol Neurosurg Psychiatry: first published as on 16 December 2004. Downloaded from patients with the primary complaint of Pain and aura dizziness, compared with 24% in a comparison group of orthopaedic Neocortex patients.1 A similar study evaluating Vertigo migraine in patients with isolated ver- tigo (n = 72) compared with orthopae- Passive coping dic controls identified migraine in 61% Thalamus of the vertigo patients but only 10% of orthopaedic patients.14 Clinical labora- tory vestibular tests in migraineurs unselected for the presence or absence of dizziness show a variety of abnorm- alities, including both peripheral and central abnormalities;12 13 15 however, Sterile "Trigeminovascular reflex" inflammation these vestibular abnormalities are more (extravasation) prominent in patients with migraine associated with dizziness.9 13 16–20 Vasodilation PAG The link between vestibular symp- of cerebral and toms and migrainous symptoms and the labyrinthine increased prevalence of vestibular test vessels abnormalities in migraineurs suggests Ophthalmic that migraine related dizziness is based Activate division Trigeminal on a specific pathophysiology—that is, trigeminal Nuc. caudalis that migraine related dizziness is a bona afferents C1/C2 dorsal horn fide disorder. In fact, Neuhauser, et al Peptide have established specific diagnostic cri- release into teria for migraine related dizziness, inner ear and which they term ‘‘migrainous vertigo’’.1 interstitial fluid Activate Vestibular A validated structured diagnostic inter- vestibular nuclei view for migrainous vertigo using these afferents criteria may help to identify this condi- tion.21 Using the Neuhauser criteria, Modulate sensitivity of: migrainous vertigo was diagnosed in 1. "Trigeminovascular reflex" 9% of migraine headache patients. In 2. Pain pathways DRN RMag 45% of these patients, migraine head- (5-HT) (5-HT) 3. Affective reactivity ache episodes were regularly accompa- http://jnnp.bmj.com/ LC (NE) LTeg (NE) nied by vestibular symptoms, and in another 48%, vestibular symptoms co- occurred irregularly.1 The influence, if any, of migraine aura on the link Figure 2 Pathogenetic model for migraine related dizziness. The core of the diagram represents between migraine and vestibular symp- pathogenetic mechanisms in migraine related pain, shown as unshaded boxes. The vestibular 4 toms is unknown. We speculate that linkages to migraine mechanisms are shaded. Adapted from Furman et al. 5-HT, 5- some episodes of vertigo in patients hydroxytryptamine (serotonin); DRN, dorsal raphe nucleus; LC, locus ceruleus; LTeg, lateral tegmental noradrenergic neurones; NE, norepinephrine; PAG, periacqueductal grey; RMag, with MARD represent migraine aura on October 1, 2021 by guest. Protected copyright. nucleus raphe magnus. without headache. do not in themselves identify the dis- (including serotonin, norepinephrine Pathophysiology of migraine order. For example, dizziness occurs as (noradrenaline), and dopamine) and related dizziness an integral or defining symptom in cutaneous allodynia, representing aber- Reflecting the uncertainty regarding the Meniere’s disease7 and panic disor- rant neurophysiology during migraine.11 pathophysiology of migraine headache, der—that is, dizziness during a panic In addition to these defining features of the pathophysiology of migraine related attack.8 Dizziness can also be considered migraine, patients often describe a dizziness is largely unknown. In fig 2, an associated symptom for migraine9 or variety of additional migraine associated we provide a framework that integrates generalised anxiety disorder.6 symptoms. One of the most common the possible neuroanatomical pathways migraine accompaniments is dizziness with the clinical manifestations of MIGRAINE RELATED DIZZINESS or balance disturbance. Dizziness occurs migrainous vertigo. Fundamental to The term ‘‘migraine’’ refers to both a in 28230% and vertigo in 25226% of the pathophysiology of migraine is the syndrome and a disorder. The diagnosis patients with a primary complaint of trigeminovascular reflex. This is a para- of migraine syndrome requires the pre- migraine.912The
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/07/13/jpet.118.250969.DC1 1521-0103/367/1/28–39$35.00 https://doi.org/10.1124/jpet.118.250969 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 367:28–39, October 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine s Carmen Nanclares, Isabel Gameiro-Ros, Iago Méndez-López, Carmen Martínez-Ramírez, J. Fernando Padín-Nogueira, Inés Colmena, Andrés M. Baraibar, Luis Gandía,1 and Antonio G. García1 Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Downloaded from Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.) Received May 28, 2018; accepted July 12, 2018 ABSTRACT jpet.aspetjournals.org The inhibition of nicotinic acetylcholine receptors (nAChRs) partially use dependent. The ACh-elicited membrane depolar- 21 has been proposed as a potential strategy to develop new antide- ization, the elevation of cytosolic calcium ([Ca ]c), and cate- pressant drugs. This is based on the observation that antide- cholamine release in BCCs were also blocked by duloxetine. This pressants that selectively block noradrenaline (NA) or serotonin blockade developed slowly, and the recovery of secretion was (5-HT) reuptake also inhibit nAChRs.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Addendum to Clinical Guideline 150, Headaches in Over 12S: Diagnosis and Management
    National Institute for Health and Care Excellence DocumentFinal information (version number/stage of process) Addendum to Clinical Guideline 150, Headaches in over 12s: diagnosis and management Clinical Guideline Addendum 150.1 Methods, evidence and recommendations November 2015 Final version Developed by the National Institute for Health and Care Excellence Clinical Guideline 150.1 (Headaches(Headaches)) Contents Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Copyright © National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE. Clinical guideline 150.1 (Headaches) Contents Contents Clinical guidelines update .................................................................................................. 6 1 Summary section.......................................................................................................... 7 1.1 Update information ................................................................................................ 7 1.2 Patient-centred care .............................................................................................
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]